Does Tufts Health Plan Cover Forteo?

How Tufts Health Plan Classifies Forteo on Its Formulary

Tufts Health Plan places Forteo on its specialty tier, typically Tier 4 or Tier 5 depending on your specific plan design. This classification reflects both the drug's high cost (wholesale acquisition cost exceeds $4,100 per pen for a 28-day supply) and its delivery method as a daily self-injection.

Tufts Health Plan operates several distinct product lines, including Tufts Health Plan Commercial, Tufts Health Plan Senior Care Options (SCO), and Tufts Medicare Preferred. Each product line maintains its own formulary, and Forteo's placement can differ across them. On commercial plans, Forteo typically sits on the specialty tier with cost-sharing that includes a percentage-based coinsurance rather than a flat copay. Medicare Preferred plans follow the CMS Part D formulary structure, which places teriparatide on Tier 5 (specialty) with a coverage gap (the so-called "donut hole") that affects total annual spending [1].

The Endocrine Society's 2020 clinical practice guidelines recommend anabolic agents like teriparatide as first-line therapy for patients at very high fracture risk, defined as a recent osteoporotic fracture, a T-score of -3.0 or below, or a high FRAX score [2]. This recommendation has influenced payer policies, though most insurers, Tufts included, still require a trial of less expensive antiresorptive therapy first.

Prior Authorization Requirements for Forteo

Prior authorization is mandatory for Forteo under all Tufts Health Plan products. Your prescribing physician must submit clinical documentation proving medical necessity before the plan will approve coverage.

Tufts Health Plan's prior authorization criteria for Forteo generally require the following: a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip; documented intolerance to, contraindication for, or inadequate response to at least one oral bisphosphonate (alendronate or risedronate) taken for a minimum of 12 months; and the prescriber must be an endocrinologist, rheumatologist, or other specialist in metabolic bone disease, or the request must include documentation of specialist consultation.

A 2019 analysis published in the Journal of Managed Care & Specialty Pharmacy found that prior authorization for osteoporosis anabolic agents delayed treatment initiation by a median of 23 days, and approximately 30% of initial requests were denied [3]. The study highlighted that incomplete documentation, not clinical ineligibility, accounted for 62% of first-round denials.

Your physician's office should expect the authorization process to take 5 to 15 business days. Tufts uses both internal medical directors and contracted pharmacy benefit managers to adjudicate specialty drug requests.

Step Therapy: What You Must Try First

Step therapy protocols require patients to use less expensive medications before the plan authorizes a costlier alternative. Tufts Health Plan applies step therapy to Forteo across nearly all of its plan types.

The standard step therapy sequence at Tufts requires a documented trial of at least one oral bisphosphonate. Alendronate (generic Fosamax) is the most commonly required first step because its wholesale acquisition cost is under $15 per month, compared to Forteo's cost exceeding $4,100. Risedronate (Actonel) or ibandronate (Boniva) may also satisfy the step requirement.

An "adequate trial" typically means 12 months of consistent use with documented adherence and a follow-up DXA scan showing continued bone loss or a new fragility fracture during treatment. The key Fracture Prevention Trial that led to Forteo's FDA approval enrolled patients with prior vertebral fractures and demonstrated a 65% reduction in new vertebral fractures and a 53% reduction in nonvertebral fractures over a median 19-month treatment period compared to placebo [4].

Exceptions to step therapy exist. Patients with glucocorticoid-induced osteoporosis, those with multiple recent fragility fractures, and patients with a T-score of -3.5 or below may qualify for a step therapy override. The American College of Rheumatology's 2022 guideline for glucocorticoid-induced osteoporosis specifically recommends teriparatide over oral bisphosphonates for patients on prednisone doses of 7.5 mg/day or higher for three or more months [5].

What You Can Expect to Pay Out of Pocket

Your actual cost for Forteo under Tufts Health Plan depends on your specific plan design, deductible status, and whether you have reached your annual out-of-pocket maximum.

On Tufts commercial plans with specialty tier coinsurance, patients typically pay 20% to 33% of the drug's cost after meeting their deductible. For a drug with a monthly cost above $4,100, that translates to $820 to $1,353 per fill before any manufacturer assistance. However, Eli Lilly offers the Forteo Savings Card, which can reduce out-of-pocket costs to as low as $4 per month for commercially insured patients who meet eligibility criteria. This assistance does not apply to government-funded plans (Medicare, Medicaid, Tricare).

For Tufts Medicare Preferred members, cost-sharing follows the Part D benefit structure. During the initial coverage phase, specialty tier coinsurance is 25% to 33%. Once total drug spending reaches $5,030 (the 2025 threshold, adjusted annually), patients enter the coverage gap. The Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000 starting in 2025, which significantly benefits patients using high-cost specialty drugs like Forteo [6].

A practical cost comparison across Tufts plan types:

• Tufts Commercial PPO: $50 to $150/month after manufacturer coupon; $820 to $1,353 without coupon
• Tufts Commercial HMO: $75 to $200/month after coupon; similar base coinsurance
• Tufts Medicare Preferred HMO: 25% to 33% coinsurance; annual cap of $2,000 total Part D out-of-pocket
• Tufts Senior Care Options (SCO/dual-eligible): $0 to $10/month; Medicaid secondary covers most cost-sharing

How Tufts Coverage Compares to Other Massachusetts Insurers

Massachusetts has a concentrated health insurance market, and Tufts Health Plan (now part of Point32Health after its 2021 merger with Harvard Pilgrim Health Care) covers approximately 1.1 million members across the state. Comparing Forteo coverage policies across major Massachusetts insurers provides useful context.

Blue Cross Blue Shield of Massachusetts also covers Forteo on its specialty tier with prior authorization and step therapy through a bisphosphonate [7]. Harvard Pilgrim, now a sibling brand under Point32Health, maintains a nearly identical formulary to Tufts following the organizational merger; both plans use the same pharmacy benefit manager for formulary decisions. Mass General Brigham Health Plan covers Forteo with similar prior authorization criteria but occasionally allows step therapy bypass for patients with severe spinal compression fractures documented on imaging.

A key distinction: Tufts Senior Care Options, which serves dual-eligible (Medicare and Medicaid) members in Massachusetts, often provides the most generous Forteo coverage because MassHealth (Massachusetts Medicaid) picks up residual cost-sharing. Dual-eligible members frequently pay $0 to $3 per fill.

Dr. Felicia Cosman, Professor of Medicine at Columbia University and lead author of the National Osteoporosis Foundation's Clinician's Guide, has stated: "The evidence now clearly supports anabolic-first treatment strategies for patients at very high fracture risk. Insurance coverage policies have been slow to reflect this clinical reality, but we are seeing gradual improvement" [8].

The Clinical Case for Forteo: Why Your Doctor Prescribes It

Understanding the clinical evidence behind Forteo helps contextualize why your physician may pursue authorization despite the administrative burden.

Teriparatide is the only FDA-approved anabolic agent that builds new bone rather than simply slowing bone breakdown. The VERO trial (N=1,360), published in The Lancet in 2018, directly compared teriparatide to risedronate in postmenopausal women with severe osteoporosis. Teriparatide reduced new vertebral fractures by 56% compared to risedronate (relative risk 0.44 to 95% CI 0.29 to 0.68) and reduced clinical fractures by 52% over 24 months [9]. This was the first head-to-head trial showing superiority of an anabolic agent over an active bisphosphonate comparator.

The SHOTZ study examined teriparatide versus zoledronic acid and found greater gains in lumbar spine bone mineral density (BMD) with teriparatide at 12 months: 7.0% versus 4.4% [10]. At the hip, results were mixed, with zoledronic acid showing a slight advantage in total hip BMD gain.

Forteo is FDA-approved for a maximum treatment duration of 24 months, based on the original osteosarcoma signal observed in rat studies at doses 3 to 58 times the human equivalent. Post-marketing surveillance data spanning over 20 years and more than 2 million patient exposures have not confirmed an increased osteosarcoma risk in humans [11]. The 2020 label update removed the boxed warning related to osteosarcoma risk.

After completing a Forteo course, patients must transition to an antiresorptive agent (typically denosumab or a bisphosphonate) to preserve the bone density gains. The DATA-Switch trial demonstrated that sequential teriparatide followed by denosumab produced greater BMD gains at the spine (18.3%) and hip (6.6%) over four years than any other sequence [12].

How to File an Appeal If Tufts Denies Forteo Coverage

If Tufts Health Plan denies your Forteo prior authorization, you have structured appeal rights that differ by plan type.

For commercial plans, Tufts must process a first-level internal appeal within 30 calendar days of receiving your written request (15 days for urgent/concurrent appeals). If the internal appeal is denied, you can request an external review through the Massachusetts Office of Patient Protection (OPP). Massachusetts law (M.G.L. Chapter 176O, Section 13) requires external review decisions within 45 days, and the external reviewer's decision is binding on the insurer.

A strong appeal includes three elements: the prescriber's letter of medical necessity citing specific clinical guidelines (the Endocrine Society 2020 guideline or AACE/ACE 2020 recommendations are most persuasive), documentation of bisphosphonate failure or intolerance (GI adverse effects are most common, affecting 20% to 30% of oral bisphosphonate users per a 2017 meta-analysis published in Osteoporosis International [13]), and a current DXA report showing the T-score and any decline from prior scans.

For Medicare Preferred plans, the Part D appeals process applies: a coverage determination, then a redetermination, then an Independent Review Entity (IRE) review. The IRE overturns initial Part D denials roughly 40% to 50% of the time for specialty osteoporosis drugs, according to CMS data from the 2023 Part D appeals summary [14].

A practical tip: request a peer-to-peer review between your prescribing physician and the Tufts medical director before filing a formal appeal. These conversations resolve approximately one in three initial denials without requiring a written appeal.

Alternatives If Forteo Is Not Covered or Too Expensive

If you cannot obtain Forteo coverage through Tufts, several clinical and financial alternatives exist.

Tymlos (abaloparatide) is another parathyroid hormone-related peptide approved for osteoporosis. Tufts may have different formulary placement for Tymlos versus Forteo, and some plans preferentially cover one over the other. The ACTIVE trial (N=2,463) showed that abaloparatide reduced new vertebral fractures by 86% versus placebo and nonvertebral fractures by 43% [15]. Tymlos costs roughly the same as Forteo at retail.

Evenity (romosozumab) is a sclerostin inhibitor approved for postmenopausal women at high fracture risk. Given as a monthly injection for 12 months, Evenity produced a 73% reduction in vertebral fractures versus alendronate in the ARCH trial (N=4,093) [16]. Tufts typically covers Evenity under similar prior authorization criteria as Forteo.

Prolia (denosumab), while antiresorptive rather than anabolic, is covered on a lower specialty tier by most Tufts plans and may have lower cost-sharing. The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures with denosumab over 36 months [17].

Generic alendronate (Fosamax) remains the most affordable first-line option at under $15 per month. The Fracture Intervention Trial showed a 47% reduction in vertebral fractures with alendronate over three years [18].

Eli Lilly's Forteo Patient Assistance Program provides free medication to uninsured or underinsured patients with household incomes below 300% of the federal poverty level. Application forms are available through the Lilly Cares Foundation.

Biosimilar Teriparatide: Will It Change Coverage?

Biosimilar teriparatide (Terrosa, manufactured by Gedeon Richter) received FDA approval in 2023, potentially opening a path to lower-cost anabolic bone therapy.

Biosimilar entry typically reduces specialty drug costs by 15% to 30% in the first two years of availability, based on patterns observed with biosimilar adalimumab and infliximab [19]. If Tufts adds a biosimilar teriparatide to its formulary at preferred tier placement, patient cost-sharing could drop substantially. Payers often create financial incentives (lower copays, waived step therapy) to shift prescribing toward biosimilars.

As of early 2026, biosimilar teriparatide distribution in the United States remains limited. Tufts has not yet added a teriparatide biosimilar to its formulary across all plan types, but formulary updates occur quarterly, and your pharmacist or Tufts member services (1-800-462-0224) can confirm the most current status.

The Endocrine Society's 2020 guideline does not distinguish between branded teriparatide and biosimilar versions, noting that biosimilars must demonstrate equivalent efficacy and safety through rigorous FDA review pathways [2].